Strategies for prevention of neonatal chronic lung disease

Seminars in Perinatology

Volumn 24, Issue 6, 2000, Pages 445-462

  Cole, Cynthia H ^a,b   Fiascone, John M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box #44 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DIURETIC AGENT; GLUCOCORTICOID; INOSITOL; NITRIC OXIDE; PROTIRELIN; RETINOL; STEROID; SUPEROXIDE DISMUTASE;

ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; FETUS LUNG MATURATION; FLUID THERAPY; GESTATIONAL AGE; HIGH FREQUENCY VENTILATION; HUMAN; INFECTION; INFLAMMATION; LIQUID VENTILATION; LUNG INJURY; NEWBORN; PATHOPHYSIOLOGY; PREMATURITY; PRIORITY JOURNAL; REVIEW; SEPSIS; STEROID THERAPY;

EID: 0034519166     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/sper.2000.20083     Document Type: Article

References (154)

1. Antenatal corticosteroid therapy: A metaanalysis of the randomized trials, 1972 to 1994
2. Neonatal chronic lung disease and exogenous surfactant therapy
3. Bronchopulmonary dysplasia in the 1990s: A Review for the Pediatrician
4. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia
5. Bronchopulmonary dysplasia-No Simple Solution
6. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease
7. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia
8. Bronchopulmonary dysplasia
9. Bronchopulmonary dysplasia: Pre- and Post-natal Influences and Outcome
10. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease?
11. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period
12. Atypical chronic lung disease patterns in neonates
13. Mechanisms initiating lung injury in the preterm
14. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops
15. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers
16. Rate of bronchopulmonary dysplasia as a function of neonatal intensive care practices
17. Association of pulmonary inflammation and increased microvascular permeability, during the development of bronchopulmonary dysplasia: A sequential analysis of inflammatory mediators in respiratory fluids of high risk preterm neonates
18. Pathogenesis of bronchopulmonary dysplasia
19. Prevention of Premature Birth
20. Etiologies of preterm birth in an indigent population: Is prevention a logical expectation?
21. Mechanisms of Disease: Intrauterine Infection and Preterm Delivery
22. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-α, interleukin-1β, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia
23. Effect of corticosteroids for fetal maturation on perinatal outcomes
24. Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia
25. Multiple courses of antenatal corticosteroids and outcome of premature neonates
26. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep
27. Fetal lung maturation: The combined use of corticosteroids and thyrotropin-releasing hormone
28. Respiratory distress in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid
29. A randomized controlled trial of antepartum thyrotropin-releasing hormone and betamethasone in the prevention of respiratory disease in preterm infants
30. Australian collaborative trial of antenatal thyrotropin-releasing hormone (ACTOBAT) for the prevention of neonatal respiratory disease
31. Antenatal thyrotropin-releasing hormone (TRH) prior to preterm delivery
32. Neonatal chronic lung disease
33. Prenatal dexamethasone treatment improves survival of newborn rats during prolonged high O2 exposure
34. Brocnhiolar epithelial lesions induced in the premature rabbit neonates by short periods of artificial ventilation
35. Ventilator-induced lung injury
36. Mechanisms of ventilator-induced injury
37. Role of tidal volume FRC and end-Expiratory volume in the development of pulmonary edema following mechanical ventilation
38. Ventilator-related pathology in the extremely immature lung
39. Lung albumin recovery in surfactant-treated preterm ventilated lambs
40. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams
41. Hypocarbia before surfactant therapy appears to increase brochopulmonary dysplasia risk in infants with respiratory distress syndrome
42. Hypocarbia and bronchopulmonary dysplasia
43. Randomized trial of permissive hypercapnia in preterm infants
44. Permissive hypercapnia. How permissive should we be?
45. Changes in intubation rates and outcome of very Iow birth weight infants: A population study
46. Early treatment with nasal continuous positive airway pressure in very low birth weight infants
47. Ventilatory management in neonates-Science or art
48. Pulmonary surfactant therapy
49. A comparison of surfactant as immediate p.rophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation
50. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates 29 through 32 weeks' gestation
51. Porcine surfactant replacement therapy in newborns of 25-31 weeks gestation: A randomized, multicentre trial of prophylaxis versus rescue with multiple low doses. The French Collaborative Multicentre Study Group
52. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome
53. Natural vs. synthetic surfactants in neonatal respiratory distress syndrome
54. Respiratory distress syndrome
55. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity
56. Surfactant: Evolving issues
57. Too many unvalidated new therapies to prevent chronic lung disease in preterm infants
58. Controversies in high-frequency ventilation
59. Reduction in lung injury after combined surfactant and high-frequency ventilation
60. Optimizing alveolar expansion prolongs the effectiveness of exogenous surfactant therapy in the adult rabbit
61. Elective high-frequency oscillatory ventilation versus conventional ventilation in preterm infants with pulmonary dysfunction: Systematic review and meta-analyses
62. Meta-analysis of elective high frequency ventilation in preterm infants with respiratory distress syndrome
63. Randomized comparison of high frequency ventilation with high-rate intermittent positive pressure ventilation in preterm infants with respiratory failure
64. Multicentre trial of high-frequency ventilation
65. International randomized controlled trial of patient triggered ventilation in neonatal respiratory distress syndrome
66. Randomized controlled trial of patient triggered and conventional fast rate ventilation in neonatal respiratory distress syndrome
67. Proportional assist ventilation in low birth weight infants with acute respiratory disease: A comparison to assist/control and conventional mechanical ventilation
68. Intratracheal pulmonary ventilation in neonatal respiratory failure
69. Intratracheal pulmonary ventilation in premature infants and children with intractable hypercapnia
70. Is liquid ventilation a reasonable alternative?
71. Partial liquid ventilation combined with high frequency gas ventilation: Clinical breakthrough or two treatments looking for a home?
72. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group
73. Partial liquid ventilation in critically ill infants receiving extracorporeal life support
74. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure
75. Controversies in the use of inhaled nitric oxide therapy in the newborn
76. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension
77. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes
78. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia
79. Inhaled nitric oxide: A premature remedy for chronic lung disease?
80. Effects of dexamethasone and indomethacin on elastase, α1-proteinase inhibitor and fibronectin in bronchoalveolar lavage fluid from neonates
81. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease
82. Effect of dexamethasone therapy on fibronectin and albumin levels in lung secretions of infants with bronchopulmonary dysplasia
83. Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation
84. Tumor necrosis factor in the bronchoalveolar secretions of infants with respiratory, distress syndrome and the effect of dexamethasone treatment
85. The effect of corticosteroid on the beta-adrenergic receptors in bronchial smooth muscle
86. Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia
87. Pulmonary function tests and fluid balance in neonates with chronic lung disease during dexamethasone treatment
88. Dexamethasone stimulation of fetal rat lung antioxidant enzyme activity in parallel with surfactant stimulation
89. Acceleration of appearance of pulmonary surfactant in the fetal lamb by administration of corticosteroid
90. Treatment and prevention of pulmonary cellular damage with pharmacologic dose of corticosteroid
91. Postnatal glucocorticoid therapy for treatment and prevention of neonatal chronic lung disease
92. Systematic review and metaanalysis of early postnatal dexamethasone for prevention of chronic lung disease
93. Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants
94. Early postnatal dexamethasone therapy for the prevention of chronic lung disease
95. Early postnatal (< 12 hrs) dexamethasone therapy for prevention of BPD in preterm infants with RDS - A two year follow-up study
96. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: Outcome of study participants at 1-year adjusted age
97. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia
98. Links between early adrenal function and respiratory outcome in preterm infants: Airway inflammation and patent ductus arteriosus
99. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants
100. Role of inhaled glucocorticoid therapy in infants at risk for neonatal chronic lung disease
101. Inhaled versus systemic steroids in chronic oxygen dependency of preterm infants
102. Randomized trial of inhaled (INH) vs intravenous (IV) steroid in ventilator dependent preterm infants
103. Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease
104. Early inhaled glucocorticoid therapy for prevention of bronchopulmonary dysplasia
105. Effect of beclomethasone therapy on tracheal aspirate interleukin-8 and interleukin-1 receptor antagonist in preterm ventilated infants at risk for bronchopulmonary dysplasia (BPD)
106. Effect of early glucocorticoid therapy on tracheobronchial lesions in mechanically ventilated preterm infants
107. Adrenal function in premature infants during inhaled beclomethasone therapy
108. Randomized controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome
109. Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment
110. Special problems in aerosol delivery: Neonatal and pediatric considerations
111. Vitamin A supplementation in very low birth weight neonates: Rationale and evidence
112. Vitamin A to prevent bronchopulmonary dysplasia in very lowbirth-weight infants: Has the dose been too low?
113. Vitamin metabolism and requirements in the micropremie
114. The effect of vitamin E prophylaxis on the incidence and severity of bronchopulmonary dysplasia
115. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight
116. High plasma vitamin C concentrations at birth associated with low anti- oxidant status and poor outcome in premature infants
117. Evidence for safety of ascorbic acid administration to the premature infant
118. Does vitamin C cause hemolysis in premature newborn infants? Results of a multicenter double-blind, randomized controlled trial
119. Uric acid and ascorbic acid redox ratios in plasma and tracheal aspirate of preterm babies with acute and chronic lung disease
120. Early high dose antioxidant vitamins do not prevent bronchopulmonary dysplasia in premature baboons exposed to prolonged hyperoxia: A pilot study
121. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury
122. The effects of multiple doses of recombinant human CuZn Superoxide disumutase (rhSOD) in premature infants with respiratory distress syndrome (RDS)
123. Inositol supplementation in premature infants with respiratory distress syndrome
124. 1-Proteinase Inhibitor therapy for prevention of chronic lung disease of prematurity: A randomized, controlled trial
125. Undernutrition as a major contributing factor in the pathogenesis of bronchopulmonary dysplasia
126. Chemical composition and nutritional needs of the fetus at different stages of gestation
127. Oxygen toxicity in the newborn: The adverse effects of under nutrition
128. Protein metabolism in the extremely low-birth weight infant
129. Nutrition in neonatal chronic lung disease
130. Growth retardation after dexamethasone administration: Assessment by knemometry
131. Implications of nutrition in oxygen-related pulmonary diseases in the human premature infant
132. NIH workshop summary. Nutrition and the respiratory system
133. Workshop summary: Nutrition of the extremely low birth weight infant
134. How to feed the preterm infant. Current Medical Literature
135. Early parenteral feeding of amino acids
136. Lipid metabolism of the micropremie
137. Oxidation of parenteral lipid emulsion by ambient and phototherapy lights: Potential toxicity of routine parenteral feeding
138. Admixture of a multivitamin preparation to parenteral nutrition: The major contributor to in vitro generation of peroxides
139. Gut hormones and "minimal enteral feeding"
140. Effect of early feeding on maturation of the preterm infant's small intestine
141. Effect of early enteral substrate on subsequent feeding tolerance
142. Bronchopulmonary dysplasia: Possible relationship to pulmonary edema
143. Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants
144. Fluid restriction for preventing bronchopulmonary dysplasia: Reduced fluid intake during the first weeks of life improves the outcome of low-birth-weight infants
145. Treatment of bronchopulmonary dysplasia: A review
146. Late-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network
147. Role of Ureaplasma urealyticum and Chlamydia trachomatis in development of bronchopulmonary dysplasia in very low birth weight infants
148. Infection with Ureaplasma urealyticum and Mycoplasma hominis and the development of chronic lung disease in preterm infants
149. Ureaplasma urealyticum colonization, prematurity, and bronchopulmonary dysplasia